Annals of Surgical Oncology

, Volume 10, Issue 4, pp 403–407 | Cite as

Sentinel Lymph Node Biopsy for Patients With Cutaneous Desmoplastic Melanoma

  • David E. Gyorki
  • Klaus Busam
  • Kathy Panageas
  • Mary Sue Brady
  • Daniel G. Coit
Original Articles

Abstract

Background: Although desmoplastic melanoma (DM) often presents at a locally advanced stage, nodal metastases are rare. We describe our experience with lymphatic mapping and sentinel lymph node biopsy (SLNB) in patients with DM to characterize the biological behavior of these tumors.

Methods: Twenty-seven patients with cutaneous DM underwent wide excision and attempted SLNB between 1996 and 2001. All pathology was reviewed by a single dermatopathologist (KB). Clinical and histological features were recorded.

Results: There were 20 male and 7 female patients. The median age was 64 years (range, 35–83 years). The head and neck was the most commonly involved anatomical region (n = 14). The median Breslow thickness was 2.2 mm. Twenty-four patients underwent successful SLNB. No patient had a positive sentinel node. At a median follow-up of 27 months, five patients recurred (four systemic and one local); all five had undergone successful SLNB. Two of these patients died of disease, two are alive with disease, and one remains alive and disease free. No patient experienced failure in a regional nodal basin.

Conclusions:DM is a biologically distinct form of melanoma, with a very low incidence of regional lymph node metastases, either at presentation or in long-term follow-up. This biology should be considered when designing rational treatment strategies for these patients.

Key Words:

Desmoplastic melanoma Sentinel lymph node biopsy Local recurrence Survival 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Conley J, Lattes R, Orr W. Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma). Cancer 1971;28:914–36.PubMedCrossRefGoogle Scholar
  2. 2.
    Quinn MJ, Crotty KA, Thompson JF, Coates AS, O’Brien CJ, McCarthy WH. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer 1998;83:1128–35.PubMedCrossRefGoogle Scholar
  3. 3.
    Carlson JA, Dickersin GR, Sober AJ, Barnhill RL. Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases. Cancer 1995;75:478–94.PubMedCrossRefGoogle Scholar
  4. 4.
    Jain S, Allen PW. Desmoplastic malignant melanoma and its variants. A study of 45 cases. Am J Surg Pathol 1989;13:358–73.PubMedCrossRefGoogle Scholar
  5. 5.
    Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976–83.PubMedGoogle Scholar
  6. 6.
    Coit DG. How we do it: the Memorial Sloan-Kettering Cancer Center approach Cody HS Eds. Sentinel Lymph Node Biopsy. London:: Martin Dunitz, 2002: 135–41.Google Scholar
  7. 7.
    Patel SG, Coit DG, Shaha AR, et al. Sentinel lymph node biopsy for cutaneous head and neck melanomas. Arch Otolaryngol Head Neck Surg 2002;128:285–91.PubMedGoogle Scholar
  8. 8.
    Clary BM, Brady MS, Lewis JJ, Coit DG. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg 2001;233:250–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Morton DL, Chan AD. Current status of intraoperative lymphatic mapping and sentinel lymphadenectomy for melanoma: is it standard of care? J Am Coll Surg 1999;189:214–23.PubMedCrossRefGoogle Scholar
  10. 10.
    Thelmo MC, Sagebiel RW, Treseler PA, et al. Evaluation of sentinel lymph node status in spindle cell melanomas. J Am Acad Dermatol 2001;44:451–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Payne WG, Kearney R, Wells K, et al. Desmoplastic melanoma. Am Surg 2001;67:1004–6.PubMedGoogle Scholar
  12. 12.
    Jaroszewski DE, Pockaj BA, DiCaudo DJ, Bite U. The clinical behavior of desmoplastic melanoma. Am J Surg 2001;182:590–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Muller MG, van Leeuwen PA, van Diest PJ, Vuylsteke RJ, Pijpers R, Meijer S. No indication for performing sentinel node biopsy in melanoma patients with a Breslow thickness of less than 0.9 mm. Melanoma Res 2001;11:303–7.CrossRefGoogle Scholar
  14. 14.
    Skelton HG, Smith KJ, Laskin WB, et al. Desmoplastic malignant melanoma. J Am Acad Dermatol 1995;32:717–25.PubMedCrossRefGoogle Scholar
  15. 15.
    Smithers BM, McLeod GR, Little JH. Desmoplastic melanoma: patterns of recurrence. World J Surg 1992;16:186–90.PubMedCrossRefGoogle Scholar
  16. 16.
    Egbert B, Kempson R, Sagebiel R. Desmoplastic malignant melanoma. A clinicohistopathologic study of 25 cases. Cancer 1988;62:2033–41.PubMedCrossRefGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2003

Authors and Affiliations

  • David E. Gyorki
    • 1
  • Klaus Busam
    • 2
  • Kathy Panageas
    • 3
  • Mary Sue Brady
    • 2
  • Daniel G. Coit
    • 1
    • 4
  1. 1.Department of SurgeryMemorial Sloan-Kettering Cancer CenterNew York
  2. 2.Department of Surgical PathologyMemorial Sloan-Kettering Cancer CenterNew York
  3. 3.Department of BiostatisticsMemorial Sloan-Kettering Cancer CenterNew York
  4. 4.Gastric and Mixed Tumor ServiceMemorial Sloan-Kettering Cancer CenterNew York

Personalised recommendations